Seven Fleet Capital Management LP
Seven Fleet Capital Management LP is an SEC-registered investment adviser that reports managing 1 hedge fund on Form ADV. It reports $434.6 million in regulatory assets under management. Its private funds, of all types, hold $434.6 million in gross assets. Over a longer period they returned an estimated +32.6% from Q1 2026 to Q1 2026, compared with -4.6% for the S&P 500, based on 13F filings.
- Regulatory assets under management
- $434.6 millionForm ADV Item 5.F
- Gross assets of private funds
- $434.6 millionAll private fund types, Form ADV
- Hedge funds managed
- 12 private funds in total
- Employees
- 4Form ADV Item 5.A
- Registration
- SEC-registered adviserCRD 335203
- Latest Form ADV
- 07/06/2026Disciplinary disclosures: none reported
Estimated 13F portfolio performance
Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.
| Quarter | Est. 13F return | S&P 500 |
|---|---|---|
| Q1 2026 | +32.6% | -4.6% |
Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures
Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.
13F holdings as of Sep 30, 2026
The 50 largest of 85 share positions ($511,733,165) reported by Seven Fleet Capital Management LP on Form 13F for the quarter ended Sep 30, 2026, filed Nov 16, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.
Share of the reported 13F portfolio, ten largest positions
- CG Oncology Inc26.13%
- Tango Therapeutics Inc10.89%
- Revolution Medicines Inc10.61%
- Pharvaris N V4.34%
- Entera Bio LTD3.90%
- Liquidia Corporation3.53%
- Arrivent Biopharma Inc2.67%
- Enliven Therapeutics Inc2.35%
- Avalo Therapeutics Inc2.31%
- Xencor Inc2.17%
| Stock | Value | % of 13F portfolio | Shares | Shares vs prior quarter |
|---|---|---|---|---|
| CG Oncology Inc | $133,715,270 | 26.13% | 1,886,236 | Unchanged |
| Tango Therapeutics Inc | $55,709,957 | 10.89% | 2,232,864 | -30.83% |
| Revolution Medicines Inc | $54,309,333 | 10.61% | 264,588 | +9.32% |
| Pharvaris N V | $22,206,664 | 4.34% | 700,084 | -9.61% |
| Entera Bio LTD | $19,970,585 | 3.90% | 6,862,744 | +3,486.41% |
| Liquidia Corporation | $18,043,282 | 3.53% | 596,275 | +16.19% |
| Arrivent Biopharma Inc | $13,661,518 | 2.67% | 451,173 | +82.95% |
| Enliven Therapeutics Inc | $12,008,109 | 2.35% | 261,957 | -28.31% |
| Avalo Therapeutics Inc | $11,844,878 | 2.31% | 772,660 | +0.25% |
| Xencor Inc | $11,101,178 | 2.17% | 444,937 | +20.81% |
| Roivant Sciences LTD | $10,615,540 | 2.07% | 290,280 | +31.87% |
| Abivax SA | $9,830,111 | 1.92% | 99,274 | -10.83% |
| Assembly Biosciences Inc | $9,805,689 | 1.92% | 417,441 | -3.63% |
| Veradermics Inc | $9,698,400 | 1.90% | 80,000 | Unchanged |
| Protagonist Therapeutics Inc | $6,432,897 | 1.26% | 45,659 | +0.57% |
| Damora Therapeutics Inc Com SHS | $6,137,982 | 1.20% | 288,439 | New |
| Century Therapeutics Inc | $6,083,133 | 1.19% | 4,421,739 | +1.70% |
| Eupraxia Pharmaceuticals Inc | $5,207,630 | 1.02% | 572,267 | -6.31% |
| Axsome Therapeutics Inc. | $4,437,530 | 0.87% | 24,066 | -16.51% |
| Sagimet Biosciences Inc | $4,239,636 | 0.83% | 429,113 | +6.34% |
| Zentalis Pharmaceuticals Inc | $4,166,720 | 0.81% | 1,504,231 | +373.62% |
| Definium Therapeutics Inc | $4,135,105 | 0.81% | 108,647 | -26.91% |
| Dianthus Therapeutics Inc | $4,088,338 | 0.80% | 46,432 | -28.26% |
| Silence Therapeutics PLC | $3,825,500 | 0.75% | 350,000 | +482.29% |
| Tarsus Pharmaceuticals Inc | $3,814,943 | 0.75% | 48,530 | -58.55% |
| Immunic Inc | $3,660,927 | 0.72% | 687,240 | New |
| Taysha Gene Therapies Inc | $3,652,500 | 0.71% | 750,000 | -50.15% |
| Cytokinetics Inc | $3,542,531 | 0.69% | 53,748 | -54.54% |
| Minerva Neurosciences Inc | $3,354,600 | 0.66% | 1,001,373 | Unchanged |
| Relay Therapeutics Inc | $3,352,481 | 0.66% | 185,733 | +4.21% |
| Zai Lab LTD | $3,118,524 | 0.61% | 118,395 | -12.96% |
| Praxis Precision Medicines I | $3,054,711 | 0.60% | 10,489 | +39.11% |
| Cytomx Therapeutics Inc. | $2,952,283 | 0.58% | 1,085,398 | Unchanged |
| Editas Medicine Inc | $2,944,802 | 0.58% | 1,915,871 | -4.00% |
| Sab Biotherapeutics Inc | $2,386,287 | 0.47% | 752,772 | +2.27% |
| Ascendis Pharma A/s | $2,150,715 | 0.42% | 9,440 | -20.47% |
| Adlai Nortye LTD | $1,858,960 | 0.36% | 116,185 | +2.63% |
| Sutro Biopharma Inc | $1,609,292 | 0.31% | 99,894 | -37.22% |
| United Therapeutics Corp Del | $1,593,157 | 0.31% | 2,940 | New |
| Inventiva SA | $1,528,918 | 0.30% | 414,341 | +107.02% |
| Harmony Biosciences Hldgs In | $1,487,954 | 0.29% | 37,900 | New |
| An2 Therapeutics Inc | $1,352,924 | 0.26% | 254,309 | +21.71% |
| Celldex Therapeutics Inc New | $1,324,532 | 0.26% | 40,868 | -52.84% |
| Summit Therapeutics Inc | $1,296,118 | 0.25% | 76,648 | +4.57% |
| Vaxcyte Inc | $1,255,555 | 0.25% | 22,066 | -25.95% |
| Tcgx Acquisition Corp | $1,251,000 | 0.24% | 100,000 | New |
| Contineum Therapeutics Inc | $1,162,897 | 0.23% | 86,654 | +43.13% |
| Biohaven LTD | $1,084,300 | 0.21% | 81,221 | New |
| Spyre Therapeutics Inc | $1,033,727 | 0.20% | 11,611 | -12.70% |
| Inmed Pharmaceuticals Inc | $1,000,000 | 0.20% | 1,069,519 | New |
Changes since Jun 30, 2026
Comparing the share counts in the two quarter-end filings: 20 new positions, 31 sold out, 26 increased, 31 reduced and 8 unchanged.
Number of positions (a count, not dollars)
- New positions20
- Increased26
- Unchanged8
- Reduced31
- Sold out31
New positions
| Stock | Value | Shares |
|---|---|---|
| Damora Therapeutics Inc Com SHS | $6,137,982 | 288,439 |
| Immunic Inc | $3,660,927 | 687,240 |
| United Therapeutics Corp Del | $1,593,157 | 2,940 |
| Harmony Biosciences Hldgs In | $1,487,954 | 37,900 |
| Tcgx Acquisition Corp | $1,251,000 | 100,000 |
| Biohaven LTD | $1,084,300 | 81,221 |
| Inmed Pharmaceuticals Inc | $1,000,000 | 1,069,519 |
| Yarrow Bioscience Inc | $900,800 | 40,000 |
| Lisata Therapeutics Inc | $534,832 | 371,411 |
| Avalyn Pharmaceuticals Inc | $419,088 | 14,710 |
| Quince Therapeutics Inc | $371,779 | 11,989 |
| Immatics N.V | $346,810 | 39,500 |
| Obsidian Therapeutics Inc | $316,847 | 23,077 |
| Faeth Therapeutics Inc | $303,467 | 10,204 |
| Tectonic Therapeutic Inc | $279,480 | 12,000 |
| Disc Medicine Inc | $268,386 | 4,100 |
| Abeona Therapeutics Inc | $255,911 | 48,745 |
| Aclaris Therapeutics Inc | $232,492 | 44,200 |
| Inovio Pharmaceuticals Inc | $167,262 | 137,100 |
| Processa Pharmaceuticals Inc | $30,012 | 18,300 |
Sold out
| Stock | Value at Jun 30, 2026 | Shares held then |
|---|---|---|
| Mirum Pharmaceuticals Inc | $12,923,709 | 110,393 |
| Damora Therapeutics Inc | $7,398,024 | 284,430 |
| Madrigal Pharmaceuticals Inc | $2,670,252 | 4,973 |
| Relmada Therapeutics Inc | $2,409,994 | 348,265 |
| Agios Pharmaceuticals Inc | $2,111,559 | 56,900 |
| Xenon Pharmaceuticals Inc | $2,084,468 | 33,300 |
| Savara Inc | $1,904,074 | 309,103 |
| Celcuity Inc | $1,700,284 | 16,252 |
| Syndax Pharmaceuticals Inc | $1,645,046 | 77,930 |
| Structure Therapeutics Inc | $1,441,572 | 26,800 |
| Alkermes PLC | $1,220,018 | 23,285 |
| Trevi Therapeutics Inc | $833,430 | 45,598 |
| Voyager Therapeutics Inc | $771,860 | 230,406 |
| Engene Therapeutics Inc | $711,142 | 411,065 |
| Larimar Therapeutics Inc | $704,309 | 230,921 |
| Ishares TR | $681,858 | 13,800 |
| Krystal Biotech Inc | $659,343 | 1,774 |
| Evolus Inc | $541,716 | 78,057 |
| Biocryst Pharmaceuticals Inc | $510,240 | 51,024 |
| Monte Rosa Therapeutics Inc | $406,560 | 16,800 |
Largest increases
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Entera Bio LTD | +6,671,390 | +3,486.41% | $19,970,585 | 6,862,744 |
| Arrivent Biopharma Inc | +204,567 | +82.95% | $13,661,518 | 451,173 |
| Revolution Medicines Inc | +22,559 | +9.32% | $54,309,333 | 264,588 |
| Zentalis Pharmaceuticals Inc | +1,186,631 | +373.62% | $4,166,720 | 1,504,231 |
| Silence Therapeutics PLC | +289,893 | +482.29% | $3,825,500 | 350,000 |
| Roivant Sciences LTD | +70,154 | +31.87% | $10,615,540 | 290,280 |
| Liquidia Corporation | +83,069 | +16.19% | $18,043,282 | 596,275 |
| Xencor Inc | +76,632 | +20.81% | $11,101,178 | 444,937 |
| Praxis Precision Medicines I | +2,949 | +39.11% | $3,054,711 | 10,489 |
| Inventiva SA | +214,200 | +107.02% | $1,528,918 | 414,341 |
| Contineum Therapeutics Inc | +26,113 | +43.13% | $1,162,897 | 86,654 |
| Sagimet Biosciences Inc | +25,568 | +6.34% | $4,239,636 | 429,113 |
| An2 Therapeutics Inc | +45,363 | +21.71% | $1,352,924 | 254,309 |
| Beam Therapeutics Inc | +7,040 | +79.96% | $387,386 | 15,844 |
| Relay Therapeutics Inc | +7,511 | +4.21% | $3,352,481 | 185,733 |
| Amylyx Pharmaceuticals Inc | +4,018 | +27.63% | $540,038 | 18,558 |
| Century Therapeutics Inc | +73,913 | +1.70% | $6,083,133 | 4,421,739 |
| Summit Therapeutics Inc | +3,348 | +4.57% | $1,296,118 | 76,648 |
| Sab Biotherapeutics Inc | +16,695 | +2.27% | $2,386,287 | 752,772 |
| Adlai Nortye LTD | +2,978 | +2.63% | $1,858,960 | 116,185 |
Largest reductions
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Tango Therapeutics Inc | -995,280 | -30.83% | $55,709,957 | 2,232,864 |
| Tarsus Pharmaceuticals Inc | -68,537 | -58.55% | $3,814,943 | 48,530 |
| Enliven Therapeutics Inc | -103,429 | -28.31% | $12,008,109 | 261,957 |
| Cytokinetics Inc | -64,492 | -54.54% | $3,542,531 | 53,748 |
| Cogent Biosciences Inc | -128,184 | -86.90% | $618,819 | 19,326 |
| Erasca Inc | -273,031 | -88.64% | $512,748 | 34,976 |
| Taysha Gene Therapies Inc | -754,400 | -50.15% | $3,652,500 | 750,000 |
| Pharvaris N V | -74,417 | -9.61% | $22,206,664 | 700,084 |
| Dianthus Therapeutics Inc | -18,291 | -28.26% | $4,088,338 | 46,432 |
| Definium Therapeutics Inc | -40,000 | -26.91% | $4,135,105 | 108,647 |
| Celldex Therapeutics Inc New | -45,796 | -52.84% | $1,324,532 | 40,868 |
| Abivax SA | -12,060 | -10.83% | $9,830,111 | 99,274 |
| Ideaya Biosciences Inc | -29,915 | -79.00% | $305,439 | 7,950 |
| Geron Corp | -798,328 | -75.51% | $318,447 | 258,900 |
| Sutro Biopharma Inc | -59,224 | -37.22% | $1,609,292 | 99,894 |
| Axsome Therapeutics Inc. | -4,760 | -16.51% | $4,437,530 | 24,066 |
| C4 Therapeutics Inc | -241,169 | -63.27% | $466,200 | 140,000 |
| Opus Genetics Inc | -133,137 | -93.01% | $48,400 | 10,000 |
| Ascendis Pharma A/s | -2,429 | -20.47% | $2,150,715 | 9,440 |
| Zai Lab LTD | -17,621 | -12.96% | $3,118,524 | 118,395 |
Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.
From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures
Large ownership stakes (Schedule 13D and 13G)
| Company | Filing | Percent of class | Shares | Filed | Source |
|---|---|---|---|---|---|
| Entera Bio, Ltd. (the "Issuer") | 13G | 4.1% | 7,053,898 | Aug 4, 2026 | SEC.gov ↗ |
| CytomX Therapeutics, Inc. | 13G amendment | 0.5% | 1,085,398 | May 15, 2026 | SEC.gov ↗ |
| Veradermics, Inc | 13D | 0.2% | 80,000 | May 5, 2026 | SEC.gov ↗ |
| CG Oncology, Inc. | 13D amendment | 1.9% | 1,515,151 | Oct 28, 2025 | SEC.gov ↗ |
A firm files Schedule 13G (passive) or 13D (it may seek to influence the company) when it beneficially owns more than 5% of a class of a public company's shares. Each row is the firm's latest such filing for that company since Oct 28, 2025, exactly as filed, and counts shares held across the firm and its affiliates, not by any single fund. An amendment can report a stake that has fallen below 5%. Holdings may have changed since the filing date. Not verified by AltMountain. Source: U.S. Securities and Exchange Commission, EDGAR.
Hedge funds filing Form D (4)
Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.
From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures